Hanmi Pharmaceutical exports digestive disease drug technology to Eli Lilly for up to $1.26 billion

Hanmi Pharmaceutical has announced a significant technology export deal with the global U.S. pharmaceutical company Eli Lilly and Company. The agreement, disclosed on June 1st, pertains to Hanmi's sustained-release GLP-2 (Glucagon-Like Peptide-2) new drug candidate, known as 'Sonefpeglutide' (HM15912).

This collaboration represents a major milestone for Hanmi Pharmaceutical, with the total contract value potentially reaching up to $1.26 billion, equivalent to approximately 1.89 trillion Korean won. The drug candidate utilizes Hanmi Pharmaceutical's proprietary long-acting bio-platform technology.

The GLP-2 analog is designed for the treatment of various gastrointestinal disorders. Sonefpeglutide is developed to provide a long-lasting therapeutic effect, potentially reducing the frequency of administration and improving patient compliance.

Eli Lilly's involvement signifies strong confidence in the potential of Hanmi's innovative drug candidate and its underlying platform technology. This partnership is expected to accelerate the development and commercialization of Sonefpeglutide, bringing a new treatment option to patients suffering from gastrointestinal diseases.